Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025

Relay Therapeutics, Inc.

2022-FY EPS reported -$2.59 revenue$1,381,000

Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).
Cash, cash equivalents and investments ~$1.0B as of Dec 31, 2022, up from $958.1M year-end 2021.
RLY-4008 interim data: 88% ORR at pivotal dose (70 mg) in FGFR2-fusion cholangiocarcinoma; registrational path set.
Breast cancer portfolio: RLY-2608 monotherapy and combination arms ongoing; initial data expected H1 2023.
Raised $300M gross proceeds in follow-on public offering; R&D expenses $246.4M for full year 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported the fourth quarter of 2022 results: net income $67.5 million, EPS $0.56.

Period: the fourth quarter of 2022
Net income: $67.5 million
EPS: $0.56
Result: reported results

Exact text from the filing

Net loss was $67.5 million for the fourth quarter of 2022, or a net loss per share of $0.56

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported financial results for the full year 2022.

Period: the full year 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Relay Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.